In patients with head and neck cancer, PD-1 therapy enhances the functionality of cetuximab-activated PD-1+NK cells by inhibiting interactions with PD-L1-expressing tumor cells (Concha-Benavente et al., 2018). Here, CD274 is linked to neoplasm.